icon-folder.gif   Conference Reports for NATAP  
  EASL 46th Annual Meeting
March 30th - April 3rd 2011
Berlin, Germany
Back grey_arrow_rt.gif
Similar SVR Rates in IL28B CC, CT or TT Prior Relapser, Partial- or Null-responder Patients Treated with Telaprevir/Peginterferon/Ribavirin: Retrospective Analysis of the REALIZE Study
  Reported by Jules Levin
EASL 2011 Berlin March 30-April 2
S Pol,1 J Aerssens,2 S Zeuzem,3 P Andreone,4 EJ Lawitz,5 S Roberts,6 Z Younossi,7 GR Foster,8 R Focaccia,9 A Horban,10 PJ Pockros,11 R Van Heeswijk,2 S De Meyer,2 D Luo,12 M Botfield,13 M Beumont,2 G Picchio12
1Universite Paris Descartes, INSERM Unite 567, AP-HP Cochin Hospital Paris, France; 2Tibotec BVBA, Beerse, Belgium; 3Johann Wolfgang Goethe University Medical Center, Frankfurt am Main, Germany; 4Universita di Bologna, Bologna, Italy; 5Alamo Medical Research, San Antonio, TX, USA; 6Department of Gastroenterology, Alfred Hospital, Melbourne, Australia; 7Center for Liver Disease, Inova Fairfax Hospital, Falls Church, VA, USA; 8Queen Mary University of London, Institute of Cell and Molecular Science, London, UK; 9Emilio Ribas Infectious Diseases Institute, São Paulo, Brazil; 10Medical University of Warsaw, Wolska, Warsaw, Poland; 11Scripps Clinic and The Scripps Research Institute, La Jolla, CA, USA; 12Tibotec Inc., Titusville, NJ, USA; 13Vertex Pharmaceuticals Inc., Cambridge, MA, USA